Author:
Mathias S. D.,Berry P.,De Vries J.,Pascoe K.,Colwell H. H.,Chang D. J.,Askanase A. D.
Publisher
Springer Science and Business Media LLC
Subject
Health Information Management,Health Informatics
Reference33 articles.
1. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus. (1999). Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology ad hoc Committee on systemic lupus erythematosus guidelines. Arthritis Rheum, 42, 1785–1796.
2. Food and Drug Administration (2010) Guidance for Industry: Systemic Lupus Erythematosus - Developing Medical Products for Treatment.
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072063.pdf
(Accessed May 2015).
3. European Medicines Agency (2015) Guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184889.pdf
(Accessed May 2015).
4. Food and Drug Administration. (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Fed Regist, 74, 65132–65133.
5. Patrick, D. L., Burke, L. B., Gwaltney, C. J., et al. (2011). Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1--eliciting concepts for a new PRO instrument. Value Health, 14, 967–977.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献